Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies

RMD Open

Volumn 2, Issue 2, 2016, Pages

  Schwartz, Thomas ^a,b   Diederichsen, Louise Pyndt ^c   Lundberg, Ingrid E ^d   Sjaastad, Ivar ^b   Sanner, Helga ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84990038556     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000291     Document Type: Review

References (98)

1. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
2. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7:399-408.
3. Badui E, Garcia-Rubi D, Robles E, et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985;36:431-41.
4. Zöller B, Li X, Sundquist J, et al. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE 2012;7:e33442.
5. Zöller B, Li X, Sundquist J, et al. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012;12:41.
6. Stern R, Godbold JH, Chess Q, et al. ECG abnormalities in polymyositis. Arch Intern Med 1984;144:2185-9.
7. Sharratt GP, Danta G, Carson PH. Cardiac abnormality in polymyositis. Ann Rheum Dis 1977;36:575-8.
8. Gottdiener JS, Sherber HS, Hawley RJ, et al. Cardiac manifestations in polymyositis. Am J Cardiol 1978;41:1141-9.
9. Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Cardiac manifestations in dermato-polymyositis. Clin Exp Rheumatol 1996;14:373-9.
10. Taylor AJ, Wortham DC, Burge JR, et al. The heart in polymyositis: a prospective evaluation of 26 patients. Clin Cardiol 1993;16:802-8.
11. Askari AD, Huettner TL. Cardiac abnormalities in polymyositis/dermatomyositis. Semin Arthritis Rheum 1982;12:208-19.
12. Denbow CE, Lie JT, Tancredi RG, et al. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979;22:1088-92.
13. Haupt HM, Hutchins GM. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am J Cardiol 1982;50:998-1006.
14. Wang H, Liu HX, Wang YL, et al. Left ventricular diastolic dysfunction in patients with dermatomyositis without clinically evident cardiovascular disease. J Rheumatol 2014;41:495-500.
15. Lu Z, Wei Q, Ning Z, et al. Left ventricular diastolic dysfunction-early cardiac impairment in patients with polymyositis/dermatomyositis: a tissue Doppler imaging study. J Rheumatol 2013;40:1572-7.
16. Schwartz T, Sanner H, Husebye T, et al. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:766-71.
17. Schwartz T, Sanner H, Gjesdal O, et al. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis 2014;73:1805-10.
18. Diederichsen LP, Simonsen JA, Diederichsen AC, et al. Cardiac Abnormalities in Adult Patients With Polymyositis or Dermatomyositis as Assessed by Noninvasive Modalities. Arthritis Care Res (Hoboken) 2016;68:1012-20.
19. Rosenbohm A, Buckert D, Gerischer N, et al. Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. J Neurol 2015;262:949-56.
20. Buchpiguel CA, Roizemblatt S, Pastor EH, et al. Cardiac and skeletal muscle scintigraphy in dermato-and polymyositis: clinical implications. Eur J Nucl Med 1996;23:199-203.
21. Diederichsen LP, Simonsen JA, Diederichsen AC, et al. Cardiac abnormalities assessed by non-invasive techniques in patients with newly diagnosed idiopathic inflammatory myopathies. Clin Exp Rheumatol 2015;33:706-14.
22. Diederichsen LP, Diederichsen AC, Simonsen JA, et al. Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis: a Danish multicenter study. Arthritis Care Res (Hoboken) 2015;67:848-54.
23. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006;45(Suppl 4):iv18-21.
24. Gupta R, Wayangankar SA, Targoff IN, et al. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol 2011;148:261-70.
25. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012;14:275-85.
26. Dankó K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004;83:35-42.
27. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002;41:22-6.
28. Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255-86.
29. Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966;89:747-68.
30. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006;25:234-9.
31. Dobloug GC, Garen T, Brunborg C, et al. Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. Semin Arthritis Rheum 2015;45:301-8.
32. Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 2014;32:188-93.
33. Limaye V, Hakendorf P, Woodman RJ, et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012;42:191-8.
34. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986;15:168-78.
35. Huber AM, Mamyrova G, Lachenbruch PA, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2014;66:732-40.
36. de Moraes MT, de Souza FH, de Barros TB, et al. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken) 2013;65:793-9.
37. de Souza FH, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol 2014;32:82-7.
38. Wang H, Tang J, Chen X, et al. Lipid profiles in untreated patients with dermatomyositis. J Eur Acad Dermatol Venereol 2013;27:175-9.
39. Wang H, Cai Y, Cai L, et al. Altered lipid levels in untreated patients with early polymyositis. PLoS ONE 2014;9:e89827.
40. Coyle K, Rother KI, Weise M, et al. Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Pediatr 2009;155:882-7.
41. Eimer MJ, Brickman WJ, Seshadri R, et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr 2011;159:795-801.
42. Schwartz T, Sjaastad I, Flatø B, et al. In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction. Rheumatology (Oxford) 2014;53:2214-22.
43. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53:2143-54.
44. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014;47:67-76.
45. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314.
46. Odabasi Z, Yapundich R, Oh SJ. Polymyositis presenting with cardiac manifestations: report of two cases and review of the literature. Clin Neurol Neurosurg 2010;112:160-3.
47. Ohata S, Shimada T, Shimizu H, et al. Myocarditis associated with polymyositis diagnosed by gadolinium-DTPA enhanced magnetic resonance imaging. J Rheumatol 2002;29:861-2.
48. Sharma K, Orbai AM, Desai D, et al. Brief report: antisynthetase syndrome-associated myocarditis. J Card Fail 2014;20:939-45.
49. Lynch PG. Cardiac involvement in chronic polymyositis. Br Heart J 1971;33:416-19.
50. Rasmussen LH, Madsen HN, Ladefoged SD. Creatine phosphokinase MB and lactate dehydrogenase isoenzyme 1 in polymyositis. Scand J Rheumatol 1985;14:427-30.
51. Peregud-Pogorzelska M, Kazmierczak J, Brzosko M. Rhythm disturbances in the form of atrial tachycardia in a female patient with polymyositis-a case report. Angiology 2006;57:391-4.
52. Sénéchal M, Créte M, Couture C, et al. Myocardial dysfunction in polymyositis. Can J Cardiol 2006;22:869-71.
53. Rechavia E, Rotenberg Z, Fuchs J, et al. Polymyositic heart disease. Chest 1985;88:309-11.
54. Behan WM, Aitchison M, Behan PO. Pathogenesis of heart block in a fatal case of dermatomyositis. Br Heart J 1986;56:479-82.
55. Afzal A, Higgins RS, Philbin EF. Heart transplant for dilated cardiomyopathy associated with polymyositis. Heart 1999;82:e4.
56. Mavrakanas TA, Lobrinus A, Berdagué P, et al. Severe mitral valve regurgitation in polymyositis. J Clin Rheumatol 2012;18:367-9.
57. Wang H, Liu H, Yu X, et al. Left ventricle diastolic function in patients with polymyositis. Int J Cardiol 2013;168:4311-12.
58. Vinereanu D, Nicolaides E, Tweddel AC, et al. "Pure" diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail 2005;7:820-8.
59. Baicu CF, Zile MR, Aurigemma GP, et al. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005;111:2306-12.
60. Ungprasert P, Suksaranjit P, Spanuchart I, et al. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014;44:63-7.
61. Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol 2009;36:1943-6.
62. Lai YT, Dai YS, Yen MF, et al. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow-up study. Br J Dermatol 2013;168:1054-9.
63. Linos E, Fiorentino D, Lingala B, et al. Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 2013;15:R7.
64. Rai SK, Choi HK, Sayre EC, et al. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford) 2016;55:461-9.
65. Vincze M, Dér H, Kerekes G, et al. Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients. Clin Rheumatol 2014;33:1635-41.
66. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
67. Mavrogeni S, Douskou M, Manoussakis MN. Contrast-enhanced CMR imaging reveals myocardial involvement in idiopathic inflammatory myopathy without cardiac manifestations. JACC Cardiovasc Imaging 2011;4:1324-5.
68. Mavrogeni S, Bratis K, Karabela G, et al. Myocarditis during acute inflammatory myopathies: evaluation using clinical criteria and cardiac magnetic resonance imaging. Int J Cardiol 2013;164:e3-4.
69. Sado DM, Kozor R, Corr L, et al. Global myocardial edema in antisynthetase syndrome detected by cardiovascular magnetic resonance mapping techniques. Circulation 2016;133:e25-6.
70. Barth Z, Nomeland Witczak B, Schwartz T, et al. In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13. 5 years after symptom onset. Rheumatology (Oxford) 2016;55:535-43.
71. Xhyheri B, Manfrini O, Mazzolini M, et al. Heart rate variability today. Prog Cardiovasc Dis 2012;55:321-31.
72. Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008;84:68-74.
73. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012;91:206-11.
74. Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015;24:216-38.
75. Hervier B, Meyer A, Dieval C, et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013;42:1271-82.
76. Cavagna L, Nunõ L, Scirè CA, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore) 2015;94:e1144.
77. Nakanishi N, European Society of Cardiology, European Respiratory Society. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergol Int 2011;60:419-24.
78. Mann DL, Zipes DP, Libby P, et al. Braunwald's heart disease: a textbook of cardiovascular medicine. 10th edn. Saunders, 2014.
79. Hughes M, Lilleker JB, Herrick AL, et al. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis 2015;74:795-8.
80. Lewington S, Whitlock G, Clarke R, et al. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39.
81. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
82. Amezaga UM, Suarez-Almazor ME. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. CurrRheumatolRep 2012;14:428-37.
83. Gullestad L, Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012;122:23-35.
84. Zweifel M, Matozan K, Dahinden C, et al. Eotaxin/CCL11 levels correlate with myocardial fibrosis and mast cell density in native and transplanted rat hearts. Transplant Proc 2010;42:2763-6.
85. Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014;5:69-75.
86. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92:223-43.
87. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757-66.
88. Charles-Schoeman C, Amjadi SS, Paulus HE, et al. Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey. Clin Rheumatol 2012;31:1163-8.
89. Erbel R, Möhlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397-406.
90. Andrus B, Lacaille D. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014;63:2886.
91. Jindal G, Singh S, Suri D, et al. Recurrent ventricular tachycardia in a child with juvenile dermatomyositis-an unusual association. Int J Rheum Dis 2012;15:e26-7.
92. Allanore Y, Vignaux O, Arnaud L, et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006;65:249-52.
93. Touma Z, Arayssi T, Kibbi L, et al. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334-7.
94. Danieli MG, Gelardi C, Guerra F, et al. Cardiac involvement in polymyositis and dermatomyositis. Autoimmun Rev 2016;15:462-5.
95. Erlacher P, Lercher A, Falkensammer J, et al. Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. Clin Chim Acta 2001;306:27-33.
96. Aggarwal R, Lebiedz-Odrobina D, Sinha A, et al. Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol 2009;36:2711-14.
97. Schwarzmeier JD, Hamwi A, Preisel M, et al. Positive troponin T without cardiac involvement in inclusion body myositis. Hum Pathol 2005;36:917-21.
98. Cox FM, Delgado V, Verschuuren JJ, et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol 2010;257:447-51.